


CCG-63802

Cat. No.:	HY-70074		
CAS No.:	620112-78-9		
Molecular Formula:	C ₂₆ H ₁₈ N ₄ O ₂ S		
Molecular Weight:	450.51		
Target:	RGS Protein		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 1.67 mg/mL (3.71 mM; Need ultrasonic and warming)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.2197 mL	11.0985 mL	22.1971 mL
		5 mM	---	---	---
10 mM		---	---	---	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. CCG-63802 is dissolved in DMSO and diluted with 0.9% NaCl ^[3] .				

BIOLOGICAL ACTIVITY

Description	CCG-63802 is a selective, reversible and allosteric RGS4 inhibitor. CCG-63802 specifically binds to RGS4 and blocks the RGS4-Gα _o interaction, with an IC ₅₀ value of 1.9 μM ^[1] .
IC ₅₀ & Target	RGS4 1.9 μM (IC ₅₀)
In Vitro	CCG-63802 (5 μM) inhibits regulators of G-protein signaling (RGS) proteins in the presence of BK (bradykinin) and 8-Br-cGMP (membrane-permeable analogue of cGMP), HEK-293 cells start to depolarize again ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	CCG-63802 (0.05 mg/kg; intratracheal administration; once per week; 90 days) reduces RGS4 protein expression, leading to partially abrogate the attenuating effect of PGZ on airway inflammation, hyperresponsiveness (AHR), and remodeling ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Forty female BALB/c mice aged 6-8 week old ^[3]
Dosage:	0.05 mg/kg
Administration:	Intratracheal administration; once per week; 90 days
Result:	CCG 63802 treatment in OVA +PGZ + CCG group significantly reduced RGS4 protein expression compared to OVA + PGZ group (P < 0.05)

CUSTOMER VALIDATION

- Inflammation. 2018 Dec;41(6):2079-2089.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Levi L Blazer, et al. Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol Pharmacol. 2010 Sep;78(3):524-33.
- [2]. Marina Dobrivojević, et al. Interaction between bradykinin and natriuretic peptides via RGS protein activation in HEK-293 cells. Am J Physiol Cell Physiol. 2012 Dec 15;303(12):C1260-8.
- [3]. Xia Meng, et al. PPAR γ Agonist PGZ Attenuates OVA-Induced Airway Inflammation and Airway Remodeling via RGS4 Signaling in Mouse Model. Inflammation. 2018 Dec;41(6):2079-2089.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA